Suspected neurological conditions: recognition and referral (NG127)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 1 May 2019
Dementia: assessment, management and support for people living with dementia and their carers (NG97)Product type:GuidanceProgramme:NICE guidelinePublished: 20 June 2018
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 June 2018Published: 23 March 2011
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)Product type:GuidanceProgramme:NICE guidelinePublished: 20 October 2015
Suspected neurological conditions: recognition and referral (QS198)Product type:Quality standardPublished: 8 January 2021
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 February 2025
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 20 November 2024Expected publication date: 26 March 2025
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 30 April 2025
Gantenerumab for treating early Alzheimer's disease TS ID 10668Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Alzheimer's disease (early) - gantenerumab [ID6142]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Deep Brain Stimulation for AlzheimerStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Pridopidine for treating Huntington's disease TSID 12052Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC